Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000551594
Ethics application status
Approved
Date submitted
9/04/2024
Date registered
1/05/2024
Date last updated
25/07/2024
Date data sharing statement initially provided
1/05/2024
Type of registration
Retrospectively registered

Titles & IDs
Public title
Pilot testing of an online fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) intervention for adults with irritable bowel syndrome
Scientific title
Proof of concept, feasibility and acceptability of an online FODMAP intervention for adults with irritable bowel syndrome.
Secondary ID [1] 311901 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Irritable bowel syndrome 333485 0
Condition category
Condition code
Oral and Gastrointestinal 330162 330162 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The online diet program is based on an evidence-based diet, recommended as first or second line therapy in irritable bowel syndrome. The diet is the low FODMAP (fermentable, oligosaccharides, disaccharides, monosaccharides and polyols) diet. It is a 3-phase diet which involves:
• Phase 1 FODMAP restriction – restricting foods high or moderate in fructans (e.g., wheat products, onions), galacto-oligosaccharides (e.g., legumes), lactose (e.g., cows’ milk), excess fructose (e.g., honey), and polyols (e.g., pear, sugar-free gum); and swapping these for low FODMAP alternatives.
• Phase 2 FODMAP reintroduction – continuing to follow a low FODMAP diet and completing a series of food challenges to help understand which foods and FODMAPs are tolerated and which trigger symptoms
• Phase 3 FODMAP personalisation – including well tolerated foods and FODMAPs back into the diet, while restricting poorly tolerated foods and FODMAPs to a level needed to maintain symptom relief.
The online diet program is a self-directed program implemented over 12 weeks, with an online therapist (dietitian) to guide participants through the program. The content of the online FODMAP diet program is organised into six Steps to be completed over the 12-week program duration and is delivered via the e-learning platform CANVAS. Participants are provided with a link to the CANVAS platform (and access to the online diet program) by the primary researcher. The program provides all the information that participants require to follow the 3-phase FODMAP diet. They are not provided with any food or meals as part of the online diet education program.
Participants access each Step individually. They are instructed to complete one module per week over the 12-week course (i.e. 12 modules). The first two Steps are completed in weeks 1 and 2 (module 1 and 2). Step 1 provides a background understanding of IBS and the FODMAP diet and Step 2 describes Phase 1 of the FODMAP diet. Steps 3, 4 and 5 describe and guide participants through the implementation of the 3-phase FODMAP diet (Phase 1 restriction; Phase 2 reintroduction; and Phase 3 personalisation). Step 3 is completed weeks 3-6 (modules 3-6) and Steps 4 and 5 are completed weeks 7-11 (modules 7-11) of the program. Step 6 of the program is completed in the final week (week 12 - module 12) and provides information to empower participants to manage their IBS and their personalised FODMAP diet after the online program is finished.
Each Step of the program consists of information provided as text, image-based information, and as downloadable handouts/worksheets. Some steps also include interactive activities (e.g. written reflection prompts, draggable questions and knowledge check questions). At the completion of each module participants will be directed to complete homework activities and questions and submit to the dietitian for feedback. Submission of homework activities and questions is required for access to successive modules. If participants do not complete a module and/or submit related homework, the program administrator (study primary researcher) will send a reminder one day and four days after the recommended date of completion. Participants will also be able to ask the dietitian questions at any time throughout the program. The therapist (dietitian) will respond to participant homework activities and questions within 2 days of submission. Feedback provided will be guided by a response message bank developed a priori by the primary researcher (JA) and the online therapist (dietitian) for the feasibility study.
Intervention code [1] 328371 0
Lifestyle
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 337918 0
Gastrointestinal irritable bowel syndrome (IBS) symptoms
Timepoint [1] 337918 0
Assessed at the end of week 6 of the 12-week diet intervention.
Primary outcome [2] 337919 0
Total fructooligosaccharide, oligosaccharide, monosaccharide and polyol (FODMAP) intake
Timepoint [2] 337919 0
4-day food diary completed in week 6 of the online diet intervention.
Primary outcome [3] 337920 0
Online program feasibility benchmark - Completion of primary measure
Timepoint [3] 337920 0
Completion of primary measures- IBS Symptom Severity Score (IBS-SSS) at baseline and weeks 2, 4, 6, 8, 10, and 12 of the online diet intervention.
Secondary outcome [1] 433702 0
Program acceptability.
Timepoint [1] 433702 0
Post 12-week online diet program.
Secondary outcome [2] 433703 0
Gastrointestinal symptoms
Timepoint [2] 433703 0
Weekly completion of Gastrointestinal Symptom Rating Scale-IBS (GSRS-IBS) during the 12-week diet intervention.
Secondary outcome [3] 433704 0
Gastrointestinal specific anxiety
Timepoint [3] 433704 0
Second weekly completion of questionnaires i.e. baseline and weeks 2, 4, 6, 8, 10, 12 of the online diet intervention.
Secondary outcome [4] 433705 0
Somatic symptoms
Timepoint [4] 433705 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [5] 433706 0
Program completion
Timepoint [5] 433706 0
Weekly assessment (12-week intervention)
Secondary outcome [6] 434217 0
Primary Outcome: Online program feasibility benchmark - Completion of primary measure
Timepoint [6] 434217 0
Primary Timepoint: Completion of composite primary measure- 4-day food diary at baseline and weeks 2, 4, and 6; and Comprehensive Nutrition Assessment Questionnaire (CNAQ) at 2 timepoints during the study i.e. weeks 9 and 12 of the online diet intervention.
Secondary outcome [7] 434218 0
Primary Outcome: Online program feasibility benchmark – Program engagement
Timepoint [7] 434218 0
Primary timepoint: Program engagement - data records from online platform CANVAS collected during 12-week online program.
Secondary outcome [8] 434220 0
Primary Outcome: Online program feasibility benchmark – Dietitian intervention
Timepoint [8] 434220 0
Primary timepoint: Dietitian intervention - data records from online platform CANVAS and dietitian records collected during 12-week online program.
Secondary outcome [9] 434221 0
Primary Outcome: Online program feasibility benchmark - Acceptability
Timepoint [9] 434221 0
Primary timepoint: Acceptability -questionnaire via 5-pt Likert scale completed post completion of 12-week online program.
Secondary outcome [10] 434222 0
Gastrointestinal Symptoms
Timepoint [10] 434222 0
Weekly completion of completion of IBS Symptom Severity Score (IBS-SSS) questionnaire during the 12-week diet intervention.
Secondary outcome [11] 434225 0
Food avoidance behaviour
Timepoint [11] 434225 0
Second weekly completion of questionnaires i.e. baseline and weeks 2, 4, 6, 8, 10, 12 of the online diet intervention.
Secondary outcome [12] 434227 0
Depression
Timepoint [12] 434227 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [13] 434230 0
Anxiety
Timepoint [13] 434230 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [14] 434235 0
Quality of life.
Timepoint [14] 434235 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [15] 434237 0
Food and eating behaviour
Timepoint [15] 434237 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [16] 434239 0
Avoidant/restrictive food behaviour
Timepoint [16] 434239 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [17] 434241 0
Physical activity
Timepoint [17] 434241 0
Baseline, mid treatment (week 6) and end of treatment (week 12)
Secondary outcome [18] 434242 0
Illness perception
Timepoint [18] 434242 0
Baseline, mid treatment (week 6) and end of treatment (week 12)

Eligibility
Key inclusion criteria
Adults aged 18 years or older with self-reported IBS which meets ROME IV criteria. Potential participants must be symptomatic at time of recruitment as indicated by a symptom severity score >75 measured using the IBS-SSS (IBS Symptom Severity Score)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
• Presence or known history of other GI diseases i.e. coeliac disease or inflammatory bowel disease) or history of major GI surgery (except appendectomy or haemorrhoidectomy).
• Presence of major comorbidities that could explain current gastrointestinal symptoms i.e. severe diabetic, cardiac, liver, neurological, neuropathy disease.
• Alarm symptoms (e.g. blood in stool, rapid weight loss, nocturnal symptoms, recent change in bowel habits if >50 years) shown to predict presence of organic diseases.
• Less than 2 years of IBS symptoms regardless of when diagnosis given
• History or current diagnosis of anorexia nervosa, binge eating disorder or bulimia nervosa). Participants with avoidant/restrictive food intake disorder (ARFID) or milder forms of disordered eating may be included.
• History or current diagnosis of psychotic disorder or bipolar disorder; current diagnosis of substance abuse disorder or major depressive disorder or active suicidal ideation.
• Body Mass Index (BMI) < 18.5kg/m2
• Pregnant or lactating or plans to become pregnant during study duration
• Currently on a restriction/elimination diet for gastrointestinal symptoms (e.g. low FODMAP diet, gluten free diet) or have undertaken the 3-phase low FODMAP diet delivered by a dietitian within the last two years. Those following a lactose free diet will be eligible if they agree to keep intake consistent unless advised to reduce further.
• Current enteral/parenteral feeding or use of supplemental feeds (e.g. Ensure)
• Currently undertaking brain-gut behaviour therapy (e.g. gut-directed hypnotherapy; gut-directed psychotherapy; mindfulness-based stress reduction; mindfulness-based cognitive therapy). Participants engaged in regular stress reduction activities such as breathing exercises, psychology counselling, mindfulness, and/or physical activity will be encouraged to continue with these activities during the 12-week intervention program.
• Commenced or change in dose of IBS medications (e.g. antidepressants) in the three months preceding study commencement.
• Commenced or change in dose of antibiotics and medications that potentially affect the gastrointestinal transit (e.g. anti-diarrhoeals and laxatives) in the month preceding study commencement. Supplements such as probiotics, prebiotics, fibre supplements and digestive enzymes will be allowed, provided that participants have been on a stable dose for at least 1 month before inclusion.
• Not willing to change current diet or dietary supplement intake (e.g. fibre supplements)
• No access to internet or computer
• Insufficient language or computer skills to complete a text based online treatment.
• Inability to provide informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
20/03/2024
Date of last participant enrolment
Anticipated
31/05/2024
Actual
23/03/2024
Date of last data collection
Anticipated
6/09/2024
Actual
Sample size
Target
20
Accrual to date
Final
8
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC
Recruitment outside Australia
Country [1] 26241 0
United States of America
State/province [1] 26241 0

Funding & Sponsors
Funding source category [1] 316252 0
University
Name [1] 316252 0
Monash University
Country [1] 316252 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 318437 0
None
Name [1] 318437 0
Address [1] 318437 0
Country [1] 318437 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 315070 0
Monash University Human Research Ethics Committee
Ethics committee address [1] 315070 0
Ethics committee country [1] 315070 0
Australia
Date submitted for ethics approval [1] 315070 0
13/12/2023
Approval date [1] 315070 0
03/01/2024
Ethics approval number [1] 315070 0
38218

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 133582 0
Dr Jessica Biesiekierski
Address 133582 0
Monash University BASE Facility 264 Ferntree Gully Rd, Notting Hill VIC 3168
Country 133582 0
Australia
Phone 133582 0
+61 0399024269
Fax 133582 0
Email 133582 0
[email protected]
Contact person for public queries
Name 133583 0
Jessica Biesiekierski
Address 133583 0
Monash University BASE Facility 264 Ferntree Gully Rd, Notting Hill VIC 3168
Country 133583 0
Australia
Phone 133583 0
+61 0399024269
Fax 133583 0
Email 133583 0
[email protected]
Contact person for scientific queries
Name 133584 0
Jessica Biesiekierski
Address 133584 0
Monash University BASE Facility 264 Ferntree Gully Rd, Notting Hill VIC 3168
Country 133584 0
Australia
Phone 133584 0
+61 0399024269
Fax 133584 0
Email 133584 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All of the individual participant data collected during the trial, after de-identification
When will data be available (start and end dates)?
Immediately following publication, no end date
Available to whom?
Only researchers who provide a methodologically sound proposal or case-by-case basis at the discretion of Primary Sponsor
Available for what types of analyses?
Only to achieve the aims in the approved proposal
How or where can data be obtained?
Access subject to approvals by Principal Investigator [email protected]


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
22146Study protocol  [email protected]
22147Informed consent form  [email protected]
22148Ethical approval  [email protected]
22149Statistical analysis plan  [email protected]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.